- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 491/113 - Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Patent holdings for IPC class C07D 491/113
Total number of patents in this class: 363
10-year publication summary
|
23
|
26
|
27
|
22
|
14
|
23
|
20
|
27
|
19
|
7
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Achillion Pharmaceuticals, Inc. | 162 |
30 |
| Alkermes Pharma Ireland Limited | 256 |
15 |
| Gilead Sciences, Inc. | 2171 |
11 |
| Bristol-myers Squibb Company | 4821 |
8 |
| Arbutus Biopharma Corporation | 170 |
8 |
| Bayer Cropscience AG | 1904 |
7 |
| Astellas Pharma Inc. | 1041 |
6 |
| Inthera Bioscience AG | 11 |
6 |
| F. Hoffmann-La Roche AG | 7847 |
5 |
| The Regents of the University of California | 20502 |
5 |
| Kinki University | 243 |
5 |
| Nippon Chemiphar Co., Ltd. | 225 |
5 |
| Shionogi & Co., Ltd. | 830 |
5 |
| Merck Sharp & Dohme LLC | 3719 |
5 |
| Janssen Pharmaceutica N.V. | 3262 |
4 |
| Merck Patent GmbH | 5723 |
4 |
| Abbvie Inc. | 1848 |
4 |
| Astex Therapeutics Limited | 228 |
4 |
| Blueprint Medicines Corporation | 243 |
4 |
| KalVista Pharmaceuticals Limited | 98 |
4 |
| Other owners | 218 |